# Filing Detail

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001193125-25-076845
Filing Date
2025-04-09
Accepted
2025-04-09 16:12:16
Documents
6

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEFA14A | d938758ddefa14a.htm | DEFA14A | 32766
2 | GRAPHIC | g938758dsp002.jpg | GRAPHIC | 289665
3 | GRAPHIC | g938758dsp003.jpg | GRAPHIC | 244053
4 | GRAPHIC | g938758dsp004.jpg | GRAPHIC | 332400
5 | GRAPHIC | g938758dsp005.jpg | GRAPHIC | 399397
6 | GRAPHIC | g938758g0409213648861.jpg | GRAPHIC | 3838
| Complete submission text file | 0001193125-25-076845.txt |  | 1782100

Mailing Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020
Business Address TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV L3 6944020 972 (3) 914-8213
TEVA PHARMACEUTICAL INDUSTRIES LTD (Filer) CIK: 0000818686 (see all company filings)

EIN.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-16174 | Film No.: 25825339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)